1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Sellas Life Sciences Group Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Alliance Company Profile: Sellas Life Sciences Group Ltd

  • November 2017
  • 43 pages
  • ID: 5212414
In this report:
Immediately following the effective time, Galena stockholders are expected to own approximately ##.##% and SELLAS shareholders are expected to own approximately ##.##% of the aggregate number of shares of Galena Biopharma's common stock, each calculated on a fully-diluted basis for the combined company, except for the exclusion of ##,##,## out-of-the money Galena Biopharma warrants.

Summary

Table of Contents

Search Inside

Brief

Sellas Life Sciences Group Ltd is a late-stage biopharmaceutical company that develops additional drugs for the treatment of distinct types of cancers and central nervous system diseases. The company licensed its lead product candidate, galinpepimut-S, from Memorial Sloan-Kettering Cancer Center.

Galinpepimut-S is a cancer immunotherapeutic agent, WT1 antigen, to treat a wide range of hematological malignancies and solid tumors. Sellas Life Sciences also offers Zolpidem for basal ganglia disorders; and TR1 product candidate, a additional fusion protein to induce innate cell death mechanisms in cancer cells. The company has operational presence in the U.S. and the UK. Sellas Life Sciences is based in Hamilton, Bermuda.

Sellas Life Sciences Group Ltd - Pharmaceuticals & Healthcare - Transactions and Alliances Profile offers you detailled data and trend analysis of the company's Mergers and Acquisitions, alliances and financings. The study offers exhaustive data on Private Equity, Mergers and Acquisitions, Venture Financing, Equity/Debt Offerings, Venture Financing and Partnership transactions reported by the firm over a 5-year period. The study provides extensive comparative data on: number of transactions, their values -subdivided into transactions types-, sub-sectors and areas.

GlobalData used data coming from Pharma eTrack deals database, primary and secondary research.

Overview

- Financial transactions - Analysis of the company's financial transactions including mergers and Acquisitions, Equity/Corporate debt offerings, Private equity investment, Venture capital financing and Alliances.

- Transactions by Year - Chart and table displaying information including the number of transactions and value described by the company by year, for a five year period.

- Transactions by Category - Chart and table depicting info containing the number of business deals and value announced by the company by type including Mergers and Acquisitions, Equity/Corporate debt offering etc.

- Transactions by Region - Chart and table presenting data on the number of accords and value described by the company by region, which comprises North America continent, Europe (EU), Asia Pacific (APAC), the Middle East (ME) and African continent and South and Central America.

- Transactions by Sub-sector - Chart and table showing data on the number of transactions and value announced by the company, by sub-sector.

- Main deals - Data on the company's main financial deals. Each such deal has a short statement, business deal type, deal justification; and deal financials and target company's main financial metrics and ratios.

- Business overview - A succinct description of the company's opertations.

- Main employees - A list of the main executives of the company.

- Significant locations and Subsidiaries - An inventory and contact details of main centers of operation and key partners (subsidiaries of the company).

- Main competitors - A list of the main competitors of the company.

- Main new developments - A succinct on latest news about the company.

Great reasons to purchase

Access comprehensive data on the company's financial transactions, company's expansion and divestiture and fund requirements

- The industry profile allows you to examine the company's financial transactions by region, by year, by industry segments and by category, for a five year period.

Gain knowledge on the growth and disinvestment strategy of the company

- The industry profile unveils transactions from the firm's core business segments' perspective to benefit you comprehend its business strategy.

Understand the main deals of the company with an overview of the recent financial transactions

- In-depth information on main recent deals includes a short statement of each deal, business deal type, deal motivation, financial deals and Target company's main financial metrics and ratios.

Get access to comprehensive data about the company's operations and detect potential clients and suppliers.

- The industry profile examines the corporate's business structure, areas and subsidiaries, main executives and key players.

Stay updated on main improvements affecting the firm

- Recent evolutions about the company exhibited in the profile advice you track main events.

Gain key aspects into the company for academic purposes or business purposes

- Highlight elements such as break up of transactions into types and info on detailed main deals are included into the industry profile to help your academic or business needs.

Note*: Some parts may be removed if info is not vailable for the company.

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 24h.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Institut Gustave Roussy - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Alliance Company Profile: Institut Gustave Roussy

  • $ 250
  • Company report
  • November 2017
  • by GlobalData

SummaryInstitut Gustave Roussy (IGR) is a cancer research institute that offers healthcare services to patients suffering from cancer and conducts research to identify new therapies. The institute provides ...

Cancer Research Institute - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Alliance Company Profile: Cancer Research Institute

  • $ 250
  • Company report
  • October 2017
  • by GlobalData

SummaryCancer Research Institute (CRI) is a nonprofit cancer research organization that discovers and develops immunotherapy for treating various types of cancer. The organization offers clinical trials ...

Clovis Oncology Inc (CLVS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Alliance Company Profile: Clovis Oncology Inc

  • $ 250
  • Company report
  • November 2017
  • by GlobalData

SummaryClovis Oncology Inc (Clovis) is a biopharmaceutical company that acquires, develops and commercializes new anti-cancer agents. The company’s development programs are targeted at specific cance ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.